Semafore Pharmaceuticals, Inc.
8496 Georgetown Road
Indianapolis
Indiana
46268
U.S.A.
Phone:
317-876-3075
Fax:
317-872-1379
|
Founded in 2000, Semafore is a small molecule drug discovery and development company that is targeting the PI3 kinase (PI3K) and PTEN cell signaling pathway to create a portfolio of innovative oncology products expected to have significant benefits over existing and developmental therapies. Increasing recognition of the central role of PI3K/PTEN in regulating cell life and death is making this pathway a prime target for drug discovery and development related to oncology, immunology and other diseases. Semafore is in pre-IND stages of drug development with a clinical candidate in its small molecule PI3K program, SF1126, expecting to enter clinical trials in late 2005 in prostate, breast, and brain cancer - cancers heavily dependent on PI3K. The company is also developing small molecule PTEN inhibitors, which have potential application in cancer and in diseases where safeguarding cell survival is crucial, including protection of the bone marrow during chemotherapy and to protect the heart from ischemia and reperfusion injury. early preclinical development in the PTEN program. Semafore has ambitious scientific and business development programs well underway. Semafore is developing a leadership position in PI3K/PTEN pathway expertise, discovery platforms, and drug products, and is assembling the core people required to discover and develop the next generation of cancer therapies.
Pathway: Genetic aberrations in signaling pathways are the best current indicators of success for therapy, and there are more genetic aberrations in the PI3K pathway than any other pathway.
Products: Semafore has a lead clinical candidate (SF1126 - PI3K Inhibitor) and has established a solid preclinical pipeline of small molecule PI3K and PTEN inhibitors with multi-billion dollar commercial potential.
Platforms: Semafore is applying its small molecule drug discovery engine to simultaneously exploit the Interceptors(tm) PI3K inhibitor and MarrowShield(tm) PTEN inhibitor platforms.
People: Combining biology, chemistry, drug development and entrepreneurial experience with support from world-leading scientific & clinical thought leaders Semafore is well positioned to execute its near-term strategy.
Semafore's lead products are expected to have significant efficacy advantages compared to existing and developmental cancer therapies. For more information, see the company's Web site www.semaforepharma.com.
Last Updated: 03-28-05
Email:
CompanyInfo@semaforepharma.com
Ownership:
Web Site:
Semafore Pharmaceuticals, Inc.
Employees:
Symbol:
|
|
|
Company News |
Semafore Pharmaceuticals, Inc. Reports Encouraging Phase I Data at American Society of Hematology for Novel PI3K/mTOR Pathway Inhibitor
12/8/2009 9:36:29 AM
More...
|
Semafore Pharmaceuticals, Inc. Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st American Society of Hematology Annual Meeting
11/16/2009 9:25:08 AM
More...
|
Semafore Pharmaceuticals, Inc. Retains Management Consulting Firm; Names Principal to Key Management Position
9/21/2009 9:37:07 AM
More...
|
Clinical Data on Semafore Pharmaceuticals, Inc.'s SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 American Society of Clinical Oncology Meeting
5/20/2009 8:48:42 AM
More...
|
Semafore Pharmaceuticals, Inc. Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
3/17/2009 10:27:43 AM
More...
|
Semafore Pharmaceuticals, Inc. Broadens Pipeline With Multi-Targeted Kinase Inhibitors
8/27/2008 9:52:04 AM
More...
|
SF1126, Semafore Pharmaceuticals, Inc.'s PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Line
8/27/2008 9:29:05 AM
More...
|
Semafore Pharmaceuticals, Inc. Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
6/4/2008 8:59:48 AM
More...
|
Semafore Pharmaceuticals, Inc.'s PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4/14/2008 9:43:36 AM
More...
|
Semafore Pharmaceuticals, Inc.'s SF1126 Exhibits Antitumor and Antiangiogenic Activity
1/9/2008 7:47:19 AM
More...
|
|
|
|